Effect of ruxolitinib when given before allogeneic stem cell transplant in patients with myelofibrosis

Trial Profile

Effect of ruxolitinib when given before allogeneic stem cell transplant in patients with myelofibrosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2015

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top